|
| |
Inpharmatica licenses
Biopendium(TM) to Schering AG and announces druggability collaboration
Second large scale agreement
on target druggability assessment
London, UK, 17th October 2005 - Inpharmatica Ltd, a leading provider of
discovery technologies and services, today announces that scientists from
Schering AG, Germany and Inpharmatica Ltd will collaborate in the area of
protein structures with the aim to prioritise proteins as drug targets.
Inpharmatica will make its Biopendium(TM) as well as Chematica(TM) technologies
available to Schering. The objective is to develop techniques and approaches
which will support Schering AG's project prioritisation activities. This is the
second such contract won by Inpharmatica and follows an agreement signed with
Pfizer in January 2005 to assess druggability of a range of nominated proteins.
The financial terms of the agreement were not disclosed.
Biopendium provides comprehensive sequence annotation for over 150 organisms,
making it the world's pre-eminent pre-computed, annotation database. Superior
annotation is generated by moving beyond traditional text-based data to a system
that incorporates pharmaceutically relevant, protein 3D structure and ligand
information.
Chematica and Biopendium are integral components of Inpharmatica's
gene-to-candidate technology platform which integrates biology- and
chemistry-based drug discovery activities. Inpharmatica's technologies optimise
target selection based on druggability, and enable rapid identification of hits
and selection of high quality leads and pre-clinical candidates, which are
prioritised on the basis of good drug-like characteristics and clinical
indication.
Commenting on the announcement, John Lisle, CEO of Inpharmatica, said: "Target
druggability assessment is essential for efficient drug development.
Inpharmatica has made a significant investment in this area in recent years
culminating in our first collaboration in the area earlier this year. We now
look forward to this opportunity to collaborate with Schering AG in this
exciting area, creating a valuable support to drug discovery decision making."
About Inpharmatica:
www.inpharmatica.com
Founded in 1998, Inpharmatica uses predictive informatics in genomics, medicinal
chemistry and ADME to improve the speed and productivity of drug discovery. The
company employs around 100 professionals at its UK locations in London and
Cambridge, with business development in North America and Japan. Inpharmatica's
unique proprietary technologies and skills are utilised in major discovery
laboratories worldwide including Serono, Pfizer, GSK, Novartis, Sanofi-Aventis,
P&G Pharmaceuticals, and Daiichi.
Inpharmatica is unique in offering discovery technologies and services which
span the full breadth of research from gene through to candidate selection: the
core elements are fully integrated, enabling customers to access the full
end-to-end technologies, or individual components and services as required.
For more information, please contact:
Andrew Lloyd & Associates
Andrew Lloyd / Heidi Thompson
Tel: +44 1273 675100
allo@ala.com /
heidi@ala.com
Inpharmatica Ltd
John Lisle, Chief Executive Officer
Tel: +44 (0)20 7074 4600
Dr Vimal Mehta, Sr. VP Business Development
Tel: +1 203 453 6525 | |
|
